| Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. | |
| | |
MedLine Citation:
|
PMID: 12107222 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Glucocorticoid remediable hyperaldosteronism (GRA) is a monogenic form of inherited hypertension caused by a chimeric gene originating from an unequal cross-over between the 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes. GRA is characterized by high plasma levels of aldosterone (regulated by ACTH) with suppressed plasma renin activity and the production of two rare steroids, 18hydroxycortisol and 18oxocortisol. Affected patients usually show severe hypertension and an elevated frequency of stroke at a young age. Affected women have a high risk of developing preeclampsia during pregnancy. Here, we describe a 5-generation pedigree from Sardinia in which the presence of the chimeric gene is demonstrated in 4 generations. This family displays a mild phenotype with average blood pressure levels of 131/86 mm Hg for GRA+ patients. The occurrence of stroke is very low, and preeclampsia was not observed in 29 pregnancies from 8 GRA+ mothers. We investigated whether the cross-over site (between the CYP11B1 and CYP11B2 genes) or biochemical characteristics could explain this phenotype. The cross-over site was located at the end of intron 3, in the same region as described in other families. We found a significant correlation between blood pressure and 18hydroxycortisol, 18oxocortisol, and plasma aldosterone levels, but not with kallikrein. However, none of the biochemical or genetic parameters investigated could explain the mild phenotype of the family. |
| | |
Authors:
|
Paolo Mulatero; Stefania Morra di Cella; Tracy A Williams; Alberto Milan; Giulio Mengozzi; Livio Chiandussi; Celso E Gomez-Sanchez; Franco Veglio |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 87 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2002 Jul |
Date Detail:
|
Created Date: 2002-07-10 Completed Date: 2002-08-02 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 3187-91 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine and Experimental Oncology, Hypertension Unit, San Vito Hospital, University of Turin, Strada San Vito 34, 10133 Turin, Italy. paolo.mulatero@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aldosterone / blood Aldosterone Synthase / genetics Blood Pressure Crossing Over, Genetic Female Glucocorticoids / therapeutic use* Humans Hydrocortisone / analogs & derivatives*, blood Hyperaldosteronism / drug therapy*, genetics*, mortality, physiopathology Italy Male Middle Aged Pedigree Phenotype Pregnancy Pregnancy Complications / physiopathology Steroid 11-beta-Hydroxylase / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Glucocorticoids; 2410-60-8/18-oxocortisol; 50-23-7/Hydrocortisone; 52-39-1/Aldosterone; 81705-06-8/18-hydroxycortisol; EC 1.14.15.4/Aldosterone Synthase; EC 1.14.15.4/Steroid 11-beta-Hydroxylase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.
Next Document: Type-2 diabetes family history delays the onset of type-1 diabetes.